We are live on ! Find out more
CRVS icon

Corvus Pharmaceuticals

88 hedge funds and large institutions have $115M invested in Corvus Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 26 increasing their positions, 23 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

145% more call options, than puts

Call options by funds: $4.72M | Put options by funds: $1.93M

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

13% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 23

4% more funds holding

Funds holding: 8588 (+3)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

5.47% less ownership

Funds ownership: 58.72%53.26% (-5.5%)

43% less capital invested

Capital invested by funds: $202M → $115M (-$86.5M)

Holders
88
Holders Change
+3
Holders Change %
+3.53%
% of All Funds
1.18%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
16
Increased
26
Reduced
23
Closed
13
Calls
$4.72M
Puts
$1.93M
Net Calls
+$2.79M
Net Calls Change
-$2.56M
Name Holding Trade Value Shares
Change
Change in
Stake
AIM
51
Avity Investment Management
Connecticut
$104K +$14.1K +3,000 +10%
Charles Schwab
52
Charles Schwab
California
$95.3K
LP
53
LMR Partners
United Kingdom
$94.9K +$141K +29,858 New
Simplex Trading
54
Simplex Trading
Illinois
$85K -$532K -112,943 -81%
Verition Fund Management
55
Verition Fund Management
Connecticut
$77.6K +$115K +24,413 New
Dimensional Fund Advisors
56
Dimensional Fund Advisors
Texas
$72.5K
OC
57
Oppenheimer & Co
New York
$71.7K +$21.1K +4,490 +25%
TBWA
58
Three Bridge Wealth Advisors
California
$71.1K
QOP
59
Quinn Opportunity Partners
Virginia
$71K
BHCM
60
Brevan Howard Capital Management
Jersey
$69.1K +$102K +21,738 New
UOC
61
UBS O'Connor
Illinois
$66.3K -$90.2K -19,150 -48%
VIA
62
Virtus Investment Advisers
Connecticut
$64.6K +$95.7K +20,315 New
LSA
63
Leonteq Securities AG
Switzerland
$64.4K +$94.2K +20,000 New
CB
64
Commerce Bank
Missouri
$63.6K
XT
65
XTX Topco
Cayman Islands
$47.6K -$199K -42,255 -74%
CM
66
Capula Management
Cayman Islands
$47K +$69.7K +14,793 New
CUAMC
67
China Universal Asset Management Company
China
$41K -$3.47K -736 -5%
Capstone Investment Advisors
68
Capstone Investment Advisors
New York
$40.2K +$59.6K +12,644 New
SFS
69
Sowell Financial Services
Arkansas
$38.2K +$56.5K +12,000 New
Group One Trading
70
Group One Trading
Illinois
$37.8K -$193K -40,873 -77%
WTC
71
WhitTier Trust Company
Nevada
$35.6K
PAS
72
PKS Advisory Services
New York
$33.4K
PCM
73
Prelude Capital Management
New York
$31.9K +$47.2K +10,027 New
RIL
74
Rothschild Investment LLC
Illinois
$22.3K
JP Morgan Chase
75
JP Morgan Chase
New York
$15.1K -$92.9K -19,716 -81%

CRVS Hedge Fund Activity: Q1 2025 in Review

88 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2025, worth a combined $115M — down 43% from $202M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new CRVS positions and 13 closed out — a net gain of 3 holders — while 26 added to existing stakes and 23 trimmed.

The largest buyer was Millennium Management, adding an estimated $6.98M. The largest seller was Samlyn Capital, cutting an estimated $12.3M.

  • 88 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2025, up from 85 in Q4 2024.
  • Funds reported $115M of Corvus Pharmaceuticals stock for Q1 2025, down 43% quarter-over-quarter.
  • 16 funds opened new Corvus Pharmaceuticals positions in Q1 2025 and 13 closed out, a net change of +3 holders.
  • The largest Corvus Pharmaceuticals buyer in Q1 2025 was Millennium Management, an estimated $6.98M added.
  • The largest Corvus Pharmaceuticals seller in Q1 2025 was Samlyn Capital, an estimated $12.3M sold.

Based on aggregated 13F filings for Q1 2025.